Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
The Supreme Court will decide if federal approval of Roundup blocks state cancer lawsuits against Bayer.
The U.S. Supreme Court will hear Bayer’s appeal in a major case over Roundup weedkiller, challenging whether the Environmental Protection Agency’s approval of glyphosate—without a cancer warning—preempts state lawsuits claiming the product causes cancer.
The case centers on a Missouri man who won a $1.25 million verdict after developing non-Hodgkin’s lymphoma from long-term Roundup use.
While the EPA maintains glyphosate is not likely carcinogenic when used as directed, some studies suggest a link, and the International Agency for Research on Cancer classifies it as “probably carcinogenic.” Bayer, which acquired Monsanto in 2018, argues federal preemption should block state claims, citing conflicting lower court rulings and seeking to limit liability.
The company has set aside $16 billion to settle claims, stopped selling glyphosate-based Roundup for residential use, and pushed for state laws banning lawsuits, with Georgia and North Dakota complying.
The Trump administration supports Bayer, reversing the Biden administration’s position.
The Court’s decision could affect about 181,000 claims and determine whether Bayer continues selling glyphosate in U.S. agriculture.
The argument date is pending.
El Tribunal Supremo decidirá si la aprobación federal de Roundup bloquea las demandas estatales por cáncer contra Bayer.